Background. Over 2 million girls and young women are living with HIV, being newly infected at disproportionately high rates. HIV infection adds risks to pregnancy, including vertical transmission and maternal death. Hormonal contraceptives are among the most effective reversible contraceptives, but they have clinically meaningful drug-drug interactions (DDI) with many antiretrovirals (ARV). MK-8591 is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) currently in Phase 2 clinical development for treatment of HIV. Unlike many ARVs, MK-8591 is not an inhibitor or inducer of major CYP enzymes and is not expected to alter the pharmacokinetics (PK) of hormonal contraceptives. This clinical study evaluated the DDI of MK-8591 with levonorgestrel (LNG) and ethinyl estradiol (EE) to support use of hormonal contraceptives with MK-8591.
Evaluation of Relationships Between UGT1A1 Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study
Background. Cabotegravir (CAB), an HIV integrase inhibitor primarily metabolized by UGT1A1, is in development as an oral tablet and long-acting (LA) intramuscular (IM) injection for the treatment and prevention of HIV infection. CAB LA has a prolonged absorption phase, typical of flip-flop PK, which yields prolonged drug exposure compared with oral administration. Genetic variation in UGT1A1 affects enzymatic activity, impacting drug exposure. A previous analysis in healthy and HIVinfected subjects demonstrated that UGT1A1 genotypes conferring poor metabolizer status were significantly associated with steady-state oral CAB PK parameters, with ~1.5-, 1.4-, and 1.3-fold increases in mean Cτ, AUC, and Cmax, respectively, in subjects with low vs. normal genetically predicted UGT1A1 activity. These increases are not considered clinically relevant. This analysis evaluated the impact of UGT1A1 genotypes on CAB PK in subjects who received both oral CAB and CAB LA in the LATTE-2 study.
Methods. DNA was genotyped for UGT1A1 in 215 HIV-infected subjects with PGx consent who received CAB LA every 4 or 8 weeks in LATTE-2. UGT1A1 variants (*6, *28, *36 and *37) were used to classify subjects with genetically predicted UGT1A1 low (n = 33), reduced (n = 100), or normal (n = 82) enzyme activity. Genetically predicted enzyme activity was assessed for association with CAB LA PK parameters at study Weeks 32 and 48. Covariates of age, weight, treatment regimen, BMI, and gender were considered, and linear regression models were applied with adjustment for significant covariates. The impact of UGT1A1 genotypes on oral and LA plasma CAB concentrations was descriptively analyzed.
Results. Genetically predicted UGT1A1 activity was statistically associated with CAB LA Cτ, AUC(0-τ), and Cmax (P < 0.05) at study Weeks 32 and 48. Mean LA PK parameters increased ~1.2-fold in subjects with low vs. normal genetically predicted UGT1A1 activity. The impact of UGT1A1 genotypes was smaller than observed for oral CAB.
Conclusion. UGT1A1 reduced function polymorphisms as anticipated had less impact on CAB PK following LA IM administration vs. oral CAB in HIV-infected patients with no requirement for CAB dose adjustment for either formulation due to UGT1A1 polymorphisms.
Disclosures. All authors: No reported disclosures. Background. Nucleoside reverse transcriptase inhibitors (NRTIs) may contribute to or exacerbate cardiovascular risk, bone loss, and renal dysfunction. Darunavir (DRV) and dolutegravir (DTG) have a high barrier to resistance and proven tolerability profile, but have not been well studied as part of an NRTI sparing regimen. The purpose of this study was to determine the real-world efficacy and safety of an NRTIsparing regimen of boosted DRV and DTG.
A Retrospective Study to
Methods. We conducted a retrospective chart review (NCT03198884) of ~400 HIV+ patients at an urban Federally Qualified Health Center to identify those who started an NRTI-sparing regimen of ritonavir(r) boosted DRV and DTG once-daily (QD). Included subjects were 3 18 years of age, receiving DRV/r QD + DTG QD for
